| Document |
Document Title |
|
WO/2021/156578A1 |
The invention relates to anti-UV molecules of natural origin, and to the process for the synthesis thereof and also the process for the synthesis of analogues thereof. More particularly, it relates to a two-step process for the synthesis...
|
|
WO/2021/142062A1 |
Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared t...
|
|
WO/2021/141969A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...
|
|
WO/2021/116608A1 |
The present invention relates to a process for the continuous synthesis of heavy alkyl acrylates by a transesterification reaction using hydrozincite as a heterogeneous catalyst.
|
|
WO/2021/113260A1 |
Provided herein are compounds and pharmaceutical compositions useful as anticholinergic compounds. Also set forth herein are methods of treating subjects in need thereof, e.g., subjects suffering from hyperhidrosis, by administering the ...
|
|
WO/2021/101508A1 |
Various salts of tranexamic acid esters compounds are described, along with compositions including such compounds. Methods of use for treatment of external surfaces (e.g. skin) and processes of producing the compounds and compositions ar...
|
|
WO/2021/089030A1 |
Disclosed are the use of one or more lipid compounds in the delivery of nucleic acids, and a lipid-nucleic acid mixture, a pharmaceutical composition or a kit comprising the lipid compound and nucleic acids. The lipid compounds provided ...
|
|
WO/2021/055835A1 |
The application relates to lipids of the general Formula (A) wherein at least one of the two side chains contains a carbonate functional group (M and/or M' is -0C(=0)0-) and to empty or loaded lipid nanoparticles (LNPs) including such li...
|
|
WO/2021/026647A1 |
Disclosed herein is a lipid having a net charge at physiological pH, and being covalently attached to a lipid moiety. The lipid moiety comprises a hydrocarbon structure having two or more linked hydrocarbon chains, optionally having cis ...
|
|
WO/2021/021634A1 |
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been di...
|
|
WO/2021/014368A1 |
According to one embodiment, there is provided a method of producing a gene modification T cell (CAR-T cells) which expresses a chimeric antigen receptor (CAR). This method includes stimulating a cell population containing a T cell with ...
|
|
WO/2021/009374A1 |
The present invention relates to ionic liquid-type compounds having formula (I). The invention also relates to the use of such compounds for the dissolution and/or extraction of at least one compound of biological origin, such as a biopo...
|
|
WO/2021/009274A1 |
The invention relates to an ethylene copolymer obtained by copolymerizing ethylene and an ion pair compound consisting of a cation of formula (I) and an anion selected from formulas (II), (III), (IV) and (V), wherein (I) where R1 = H or ...
|
|
WO/2021/004947A1 |
The invention discloses a method for preparation of acetoacetate ester compounds with amino alcohol catalysts which are themselves diketenized in the course of the diketenization reaction; and subsequent polymerization of these acetoacet...
|
|
WO/2020/254337A1 |
The invention concerns new quaternary ammonium compounds with surfactant properties and improved biodegradability.
|
|
WO/2020/243217A1 |
Described herein are pH responsive compounds, micelles, and compositions useful for the detection of primary and metastatic tumor tissues. Compounds described herein are imaging agents useful for the detection of primary and metastatic t...
|
|
WO/2020/243540A1 |
Disclosed are cationic lipids which are compounds of Formula I. Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly ca...
|
|
WO/2020/230480A1 |
The present invention addresses the problem of providing: a polymerizable liquid crystal composition that can undergo uniform vertical alignment without a PI layer being provided, can inhibit occurrence of dropping marks or alignment irr...
|
|
WO/2020/227322A1 |
Compositions comprising at least one esteramine active are disclosed in which the esteramine provides conditioning, softening, and/or cleaning properties. The compositions are useful for hair care, as well as in other applications, such ...
|
|
WO/2020/218365A1 |
[Problem] To provide a curable composition which has excellent curability, preferably can contain water that is environment-friendly, can be cured into a cured film having excellent adhesiveness to a base material, particularly to a plas...
|
|
WO/2020/219876A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/154320A1 |
The present disclosure addresses elastomeric adhesives and elastomers that include a modified amine. The modified amine can be the reaction product of an amine with a Michael acceptor. The amine can be represented by H2N-Ar-R1-NH2, where...
|
|
WO/2020/150384A1 |
Disclosed is a method of treating non-keratinous fibers using a composition comprising an amide and/or alkyl ammonium carboxylate salt wherein the treating method improves the robust performance of the non-keratinous fibers and simultane...
|
|
WO/2020/145627A1 |
Provided is a method for preparing glufosinate, comprising the steps of: preparing a first intermediate compound by reacting L-homoserine in the presence of a first acid catalyst; preparing a second intermediate compound by reacting the ...
|
|
WO/2020/118041A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/087233A1 |
Disclosed is an application of an ionic iron (III) complex as a catalyst in preparation of a benzylamine compound, that is, an ionic iron (III) complex having a molecular formula of [(RNCHCHNR)CH][FeBr4] (R is tert-butyl) and containing ...
|
|
WO/2020/075007A1 |
Provided is an addition-fragmentation agent of the formula (I) where Ramine comprises a tertiary amine group; R2 linking group of valence a+2; Z is an ethylenically unsaturated polymerizable group; and subscript a is 0 or 1.
|
|
WO/2020/072324A1 |
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for ...
|
|
WO/2020/072605A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/070403A1 |
The invention relates to the use of a stabilising compound comprising at least one N-oxyl compound and at least one polymerisation inhibitor other than an N-oxyl compound, for inhibiting transesterification catalyst degradation in a proc...
|
|
WO/2020/031836A1 |
A polymerizable ionic liquid according to the present invention includes a compound comprising: an anion that has a predetermined structure and that includes a perfluoroalkyl group and a polymerizable functional group in the molecule the...
|
|
WO/2020/023311A1 |
Processes for preparing neutral liposomes include adding a hydrophobic solution of liposome lipid bilayer precursors and a nucleic acid condenser to an aqueous composition of a nucleic acid condenser and a biologically active ingredient ...
|
|
WO/2020/014606A1 |
Described are compositions and methods for inhibiting polymerization of a monomer (e.g., styrene) composition a quinone methide polymerization retarder and an oxygen-containing amine compound that is a tertiary amine or hydroxylamine. In...
|
|
WO/2020/002162A1 |
The present invention relates to an esteramine salt according to the general formula (I): The substituents R1, R2 and R3 are defined below. The present invention further relates to a process for preparing such an esteramine salt accordin...
|
|
WO/2020/000172A1 |
The present invention relates to a process for producing an esterquat by a transesterification reaction of a fatty acid oil or a mixture comprising one or more fatty acid oils and one or more fatty acids with a tertiary hydroxy amine and...
|
|
WO/2020/005920A1 |
The present invention provides compounds used in the synthesis of chemiluminescent acridinium compounds and methods of producing these compounds. Specifically, methods are provided for the N-alkylation of acridan compounds using alkylati...
|
|
WO/2019/235635A1 |
The present invention addresses the problem of providing: a compound or a salt thereof, which constitutes lipid particles that enable the achievement of high nucleic acid encapsulation rate and excellent nucleic acid delivery; and lipid ...
|
|
WO/2018/177383A9 |
The present application relates to extracting, from a traditional Chinese medicine, a plurality of compounds capable of prompting nucleic acid delivery or synthetic compounds, and promoting nucleic acid such as sRNA to absorb and enter a...
|
|
WO/2019/218864A1 |
Disclosed is a method of preparing an organic amine ester derivative drug of 2-(α-hydroxypentyl)benzoic acid and a use thereof. In particular, the present disclosure relates to a compound represented by formula I or a pharmaceutically a...
|
|
WO/2019/219942A1 |
Provided is a process for producing an amine via a hydroaminoalkylation reaction of a non-aromatic C-C double bond or C-C triple bond, said process comprising a step of reacting a compound comprising a non-aromatic C-C double bond or C-C...
|
|
WO/2019/204808A1 |
The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or ...
|
|
WO/2019/196048A1 |
Disclosed is a method for producing 2-dimethylaminoethyl (meth)acrylate by a multistage batch reaction, comprising recycling a catalyst (DBTO) to a subsequent reaction, adding a certain amount of a fresh catalyst to the recycled catalyst...
|
|
WO/2019/184663A1 |
Provided is a preparation method for herbal medicine, comprising the following steps: mixing one or more lipid components and/or with any one or more of the following: nucleic acid, compounds, and macromolecules; and performing heat trea...
|
|
WO/2019/184991A1 |
The present invention relates to extracting multiple types of compounds or synthetic compounds capable of promoting nucleic acid delivery from a traditional Chinese medicine, promoting the absorption of a nucleic acid such as sRNA and th...
|
|
WO/2019/176079A1 |
[Problem] To provide a biodegradable compound that has a structure degraded in cells, a lipid particle comprising the biodegradable compound and a medicinal composition containing the lipid particle. [Solution] According to one embodimen...
|
|
WO/2019/117446A1 |
The present invention relates to a method for producing a 2-octylglycine ester having optical activity from a racemic 2-octyl-DL-glycine ester and, more particularly, to a method for producing a 2-octyl-L-glycine ester or a 2-octyl-D-gly...
|
|
WO/2019/105780A1 |
Composition containing (A) at least one salt of an organic ester of choline or of a derivative of choline, and (B) at least one surfactant selected from amphoteric and anionic and non-ionic surfactants.
|
|
WO/2019/098883A1 |
The invention relates to the field of medicine, pharmacology, and the chemical and pharmaceutical industry, specifically to novel polymorphic forms of trimebutine maleate and methods of producing and using same.
|
|
WO/2019/035775A1 |
A method for the preparation of tapentadol in the form of a base or its hydrogen chloride, which involves the preparation of a salt (III) from a mixture of diastereomers (II) by means of crystallization-induced asymmetric transformation ...
|
|
WO/2019/036008A1 |
Compounds are provided having the following structure: [Formula should be inserted here] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3, L1, L2, G1, G2 and G3 are as defined herein. Use of the compoun...
|
